Metformin
metformin hydrochloride
Metformin is the most widely prescribed oral antihyperglycemic in the world and the leading candidate for a clinically validated geroprotective drug. By activating AMPK and suppressing hepatic glucose output, it lowers fasting glucose without raising insulin — a metabolic profile increasingly studied in healthy adults pursuing longevity.
BiguanidePrescription requiredEvidence A
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.
Why it matters
Metformin has the deepest evidence base of any metabolic medication. UKPDS 34 (Lancet 1998) demonstrated reductions in diabetes-related mortality and macrovascular events in overweight diabetics. The Diabetes Prevention Program (NEJM 2002) showed metformin reduced progression from prediabetes to type 2 diabetes by 31%. Multiple meta-analyses suggest metformin-treated diabetics have lower all-cause mortality than matched non-diabetics — the observation that motivated the ongoing TAME trial (NCT02432287), the first FDA-sanctioned interventional trial of aging as an indication. Mechanistically, metformin activates AMPK, inhibits complex I of the mitochondrial electron transport chain, modulates the gut microbiome, and suppresses mTOR signaling — pathways central to most theories of aging. For high-performance men, metformin sits at the intersection of glycemic control, cardiovascular risk reduction, and potential lifespan extension at a cost of roughly ten dollars per month.
Uses
Label uses (approved)
- Type 2 diabetes mellitus
- Prediabetes (in select populations)
- Polycystic ovary syndrome (insulin resistance)
Off-label (educational only)
- Healthy aging / longevity — AMPK activation, reduced mTOR signaling, and observational mortality benefitmoderate
- Weight maintenance after GLP-1 discontinuation — Mild appetite suppression and improved insulin sensitivityweak
- Cancer risk reduction — Observational studies suggest lower incidence of several cancers in long-term usersweak
Dosing
Label dose
500 mg twice daily with meals, titrated up to 2000 mg/day (max 2550 mg/day for IR; 2000 mg/day for XR)
Off-label / biohacker dose
500-1500 mg/day (longevity protocols often use 500-1000 mg XR at dinner)
Titration: Start 500 mg once daily with the largest meal for 1-2 weeks, then add a second 500 mg dose. Increase by 500 mg every 1-2 weeks as GI tolerance allows. Extended-release reduces GI side effects substantially.
When to take: With largest meal (typically dinner). XR formulation taken once daily with evening meal.
Side effects & warnings
Common
- Diarrhea
- Nausea
- Abdominal cramping
- Metallic taste
- Flatulence
- Reduced appetite
- Vitamin B12 malabsorption (long-term)
Uncommon but serious
- Lactic acidosis (rare, <1 in 30,000 patient-years)
- Megaloblastic anemia from B12 deficiency
- Hypoglycemia (rare unless combined with insulin/sulfonylurea)
- Hepatotoxicity (very rare)
Serious warnings
Lactic acidosis is the most feared adverse event — risk rises sharply in patients with eGFR below 30 mL/min/1.73m2, acute kidney injury, severe heart failure, sepsis, or alcohol abuse. Hold metformin around contrast imaging, major surgery, and acute illness with dehydration. Long-term use (>4 years) causes measurable vitamin B12 deficiency in 10-30% of users — check B12 annually. Avoid in decompensated liver disease.
Biomarkers affected
apob
variableVariable effect; improvements correlate with metabolic improvements
Evidence: moderate
fasting glucose
decreaseLowers fasting glucose 20-40 mg/dL via AMPK activation and suppressed hepatic gluconeogenesis (UKPDS 34)
Evidence: strong
fasting insulin
decreaseImproves insulin sensitivity and lowers fasting insulin
Evidence: strong
hba1c
decreaseReduces HbA1c by 1.0-1.5% in diabetics; smaller reductions in prediabetes
Evidence: strong
homa ir
decreaseSubstantially improves HOMA-IR in insulin-resistant populations
Evidence: strong
hscrp
decreaseModest reductions in systemic inflammation markers
Evidence: moderate
ldl c
decreaseSmall reductions reported; not a primary lipid-lowering agent
Evidence: weak
triglycerides
decreaseModest 10-20% reduction; effect partly mediated by glycemic improvement
Evidence: moderate
Monitoring
Annual eGFR (creatinine), B12 every 1-2 years, hemoglobin A1c every 3-6 months if used for glycemic control
The honest risk picture
## What can go wrong
**Gastrointestinal intolerance** is the single most common reason people abandon metformin. Up to 25% of patients experience diarrhea, nausea, or cramping at full dose. Extended-release formulations and slow titration solve this for most.
**Vitamin B12 deficiency** is real and underappreciated. Metformin impairs B12 absorption in the ileum; 10-30% of long-term users develop deficiency over 4+ years. Untreated, this causes peripheral neuropathy that can be mistaken for diabetic neuropathy.
**Lactic acidosis** is the boxed warning. The absolute risk is low (around 3 cases per 100,000 patient-years), but mortality once it occurs is 30-50%. Risk concentrates in patients with renal impairment, acute illness, heart failure, or alcohol misuse.
**Exercise-blunting effect** matters for athletes. Several randomized trials show metformin attenuates VO2 max and hypertrophy responses to training — the same AMPK pathway that delivers metabolic benefit competes with mTOR-driven adaptation.
**Drug interactions** include contrast dye (hold around imaging), carbonic anhydrase inhibitors, and alcohol. Never combine with sulfonylureas or insulin without close glucose monitoring.
Practical context
Cost (US, retail)
$10/mo
Legality
Prescription-only in US, EU, UK. Generic and inexpensive.
Interactions
true
FAQ
Is metformin safe for long-term use in non-diabetics?+
Most longevity researchers consider metformin reasonably safe in healthy adults with normal kidney function. The TAME trial (NCT02432287) is specifically testing this question. Long-term users should monitor B12 levels and kidney function annually.
Does metformin blunt exercise gains?+
Some studies show metformin can blunt aerobic adaptations and hypertrophy responses, likely via AMPK-mediated suppression of mTOR. Athletes pursuing peak performance may want to avoid it or time doses away from training.
Will metformin make me lose weight?+
Average weight loss is modest — 2-3 kg over 6-12 months. It is not a weight-loss drug; GLP-1 receptor agonists are far more effective for that purpose.
How long until metformin works?+
Fasting glucose typically improves within 1-2 weeks. Maximum HbA1c reduction is seen at 8-12 weeks.
Can I drink alcohol on metformin?+
Moderate drinking is usually fine. Heavy or binge drinking raises lactic acidosis risk and should be avoided.
References (4)+
- UKPDS 34 - Effect of intensive blood-glucose control with metformin. Lancet 1998. https://pubmed.ncbi.nlm.nih.gov/9742976/
- TAME (Targeting Aging with Metformin) trial registration. ClinicalTrials.gov NCT02432287. https://clinicaltrials.gov/study/NCT02432287
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin (DPP). NEJM 2002. https://pubmed.ncbi.nlm.nih.gov/11832527/
- Metformin and mortality in diabetes: meta-analysis. Diabetes Obes Metab 2014. https://pubmed.ncbi.nlm.nih.gov/24299161/
The prime report
Weekly performance intelligence.
New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.